A Randomized Trial Comparing a Ventilatory Strategy To Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA vs. LADS Trial)
Launched by M.D. ANDERSON CANCER CENTER · Jan 26, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The VESPA vs. LADS trial is studying two different methods to help prevent a condition called atelectasis, which is when part of the lung collapses, during a procedure known as robotic bronchoscopy. This procedure is used to examine lung nodules that might be cancerous. The trial aims to find out if the LADS method is more effective than the VESPA method in keeping the lungs fully inflated during the procedure.
To participate in this trial, you need to be at least 18 years old and scheduled for a robotic bronchoscopy due to a lung nodule that is smaller than 3 cm. It's important that the nodule is located in specific areas of the lung and that you have had a chest CT scan within the last month. If you have certain health conditions, such as significant lung problems or are currently pregnant, you may not qualify for the study. If you join, you’ll receive one of the two ventilatory strategies during your procedure, and the team will monitor how well it works in preventing atelectasis. This trial is currently recruiting participants, so if you think you might be eligible, it could be a good opportunity to consider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patients (≥ 18 years old) undergoing diagnostic robotic bronchoscopy for a lung nodule suspicious for malignancy bronchoscopy under general anesthesia.
- • 2. Lung nodules should be up to 3 cm in diameter and located in right or left bronchial segments B2, B6, B9, and B10. Greater than 50% of the volume of the lesion needs to be below a horizontal line traced at the most anterior edge of the corresponding vertebral body.
- • 3. Chest CT performed \< 45 days prior to bronchoscopy.
- • 4. Voluntary informed consent to participate in the study.
- Exclusion Criteria:
- • 1. Patients with prior lung consolidation, interstitial changes or lung masses (\> 3 cm in diameter) as seen on most recent CT
- • 2. Lesions outside of the designated lung areas defined as inclusion criteria.
- • 3. Known pregnancy
- • 4. Vulnerable population
- • 5. Ascites
- • 6. Known diaphragmatic paralysis
- • 7. Smokers or ex-smokers with known or suspected severe air-trapping defined as residual volume \> 150% of predicted
- • 8. History of primary or secondary spontaneous pneumothorax
- • 9. Lung bullae \> 5 cm
- • 10. Patients with mediastinal or hilar adenopathy with high suspicion for malignancy in whom lymph node sampling is indicated and should occur prior to robotic bronchoscopy of the peripheral lesion.
- • 11. Patient with active COVID pneumonia.
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Roberto Casal, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials